Carlyle Group Inc.Carlyle Group Inc.

Institutional investor · Portfolio as of Q1 2025

SEC EDGAR SourceSEC Filings

Top Holdings23 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction

STANDARDAERO INC

134.4M$3.6B94.1%$27.09+0.33%
2 qtrssince 2024-Q4
Increased
100
SLNOSLNODelisted

SOLENO THERAPEUTICS INC

860,980$61.4M1.6%$26.90+167.58%
9 qtrssince 2023-Q1
Decreased
0
WRDWRD
ADR

WERIDE INC

3.4M$46.5M1.2%$13.85-57.76%
2 qtrssince 2024-Q4
Unchanged
0

PHATHOM PHARMACEUTICALS INC

3.5M$21.9M0.6%$7.87-16.19%
9 qtrssince 2023-Q1
Unchanged
0
PONYPONY
ADR

PONY AI INC

2.4M$20.8M0.5%$15.25-41.18%
2 qtrssince 2024-Q4
Unchanged
0
INVHINVH
REIT

INVITATION HOMES INC

477,500$16.6M0.4%$27.70+20.79%
9 qtrssince 2023-Q1
Unchanged
0

GETTY IMAGES HOLDINGS INC

6.2M$10.8M0.3%$5.55-67.75%
10 qtrssince 2022-Q4
Decreased
0
CUBECUBE
REIT

CUBESMART

220,500$9.4M0.2%$33.40+18.03%
11 qtrssince 2022-Q3
Unchanged
0

SEACOR MARINE HLDGS INC

1.4M$6.9M0.2%$10.64-7.72%
26 qtrssince 2018-Q4
Unchanged
0
EMEMDelisted
ADR

SMART SH GLOBAL LTD

4.4M$4.9M0.1%$1.12+0.89%
12 qtrssince 2022-Q2
Decreased
0

JASPER THERAPEUTICS INC

1.1M$4.6M0.1%$18.80-76.28%
9 qtrssince 2023-Q1
Unchanged
0

EXICURE INC

281,636$3.6M0.1%$13.76+1.70%
9 qtrssince 2023-Q1
Unchanged
0

SUNPOWER INC

2M$3.1M0.1%$1.39+10.85%
7 qtrssince 2023-Q3
Decreased
0
107,214$2.7M0.1%$35.43-45.47%
3 qtrssince 2024-Q3
Unchanged
0
HLVXHLVXDelisted

HILLEVAX INC

1.8M$2.6M0.1%
9 qtrssince 2023-Q1
Unchanged
0
2.9M$2.3M0.1%
9 qtrssince 2023-Q1
Unchanged
0

Q32 BIO INC

1.1M$1.8M0.0%$17.04-89.96%
5 qtrssince 2024-Q1
Unchanged
0

KRISPY KREME INC

340,748$1.7M0.0%$14.92-66.76%
5 qtrssince 2024-Q1
Unchanged
0

ONKURE THERAPEUTICS INC

269,895$1.2M0.0%$8.27-46.07%
2 qtrssince 2024-Q4
Unchanged
0

SPRUCE BIOSCIENCES INC

2.9M$840,2800.0%
$3.8B
AUM
23
Positions
Q1 2025
Filing
Rating · 1.5
Quarterly Portfolio Change
-10%Q4'23$2.1B-24%Q1'24$1.6B-34%Q2'24$1.1B-9%Q3'24$954.2M+335%Q4'24$4.1B-8%Q1'25$3.8B
Activity profile
$ moved · Q1'25
New0%Increased96%Decreased3%Exited0%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 1.6 years
<1Q0%1-4Q30%1-2Y17%2Y+52%

Carlyle Group Inc. manages $3.8B across 23 positions as of Q1 2025. Top holdings: SARO (94.1%), SLNO (1.6%), WRD (1.2%). Fund DNA: Concentrated Value. HoldingsIntel Rating: 1.5/5.0.

Q1 2025 Summary

Exited 4, increased 1, trimmed 5. Top move: SARO (INCREASED, conviction 100). Portfolio: $3.8B across 23 positions.

Top holdings by portfolio weight

Total AUM$4B
SARO94.10%
SLNO1.62%
WRD1.22%
PHAT0.58%
PONY0.55%
INVH0.44%
GETY0.28%
CUBE0.25%
SMHI0.18%
EM0.13%
Other0.12%

Portfolio allocation by GICS sector

Sectors8
Industrials94.35%
Healthcare2.51%
Technology1.87%
Real Estate0.69%
Communication Services0.28%
Consumer Cyclical0.13%
Unknown0.13%
Consumer Defensive0.04%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Industrials
Compare DNA across all funds
7-dimension quality assessment
Below Average(1.5 / 5.0)
Track RecordNo data
Conviction38
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used